Chen Zhong, Ye Zhenqing, Soccio Raymond E, Nakadai Tomoyoshi, Hankey William, Zhao Yue, Huang Furong, Yuan Fuwen, Wang Hongyan, Cui Zhifen, Sunkel Benjamin, Wu Dayong, Dzeng Richard K, Thomas-Ahner Jennifer M, Huang Tim H M, Clinton Steven K, Huang Jiaoti, Lazar Mitchell A, Jin Victor X, Roeder Robert G, Wang Qianben
Department of Pathology and Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Nucleic Acids Res. 2022 May 6;50(8):4450-4463. doi: 10.1093/nar/gkac246.
Mediator activates RNA polymerase II (Pol II) function during transcription, but it remains unclear whether Mediator is able to travel with Pol II and regulate Pol II transcription beyond the initiation and early elongation steps. By using in vitro and in vivo transcription recycling assays, we find that human Mediator 1 (MED1), when phosphorylated at the mammal-specific threonine 1032 by cyclin-dependent kinase 9 (CDK9), dynamically moves along with Pol II throughout the transcribed genes to drive Pol II recycling after the initial round of transcription. Mechanistically, MED31 mediates the recycling of phosphorylated MED1 and Pol II, enhancing mRNA output during the transcription recycling process. Importantly, MED1 phosphorylation increases during prostate cancer progression to the lethal phase, and pharmacological inhibition of CDK9 decreases prostate tumor growth by decreasing MED1 phosphorylation and Pol II recycling. Our results reveal a novel role of MED1 in Pol II transcription and identify phosphorylated MED1 as a targetable driver of dysregulated Pol II recycling in cancer.
中介体在转录过程中激活RNA聚合酶II(Pol II)的功能,但尚不清楚中介体是否能够与Pol II一起移动,并在起始和早期延伸步骤之后调节Pol II转录。通过使用体外和体内转录循环测定,我们发现人类中介体1(MED1)在被细胞周期蛋白依赖性激酶9(CDK9)在哺乳动物特有的苏氨酸1032位点磷酸化后,会在整个转录基因中与Pol II动态移动,以驱动第一轮转录后的Pol II循环。从机制上讲,MED31介导磷酸化的MED1和Pol II的循环,在转录循环过程中增强mRNA输出。重要的是,在前列腺癌进展到致死阶段时,MED1磷酸化增加,并且对CDK9的药理学抑制通过降低MED1磷酸化和Pol II循环来减少前列腺肿瘤生长。我们的结果揭示了MED1在Pol II转录中的新作用,并确定磷酸化的MED1是癌症中Pol II循环失调的可靶向驱动因素。